Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.

Genetically engineered radiolabeled antibody fragments have shown great promise for the radioimmunoscintigraphy of cancer. Retaining the exquisite specificity of monoclonal antibodies yet smaller in molecular size, antibody fragments display rapid tumor targeting and blood clearance, a more uniform distribution in the tumor, and present a lower potential to elicit an immune response. However, one of the factors that has limited clinical evaluation of these antibody-derived proteins has been the difficulty in expressing and purifying the quantities necessary for clinical trials. This study outlines the capability of mammalian expression for the production of recombinant antibody fragments intended for clinical use. Two anti-carcinoembryonic antigen antibody fragments, the T84.66/212 Flex minibody (scFv-C(H)3) and the T84.66 diabody (scFv dimer) have been previously expressed and have shown excellent radioimaging properties in tumor bearing animals. To proceed toward human studies, these high affinity recombinant fragments and a second minibody version, the T84.66/GS18 Flex minibody, were expressed using a high-level mammalian expression system. Production of all three antibody fragments in a small-scale hollow fiber bioreactor resulted in 137-307 mg of crude antibody harvest. A purification protocol that employed ceramic hydroxyapatite and anion exchange chromatography resulted in 50-150 mg of purified T84.66 diabody and T84.66 minibody. The development of this level of research grade material established conditions for clinical production as well as provided material to complete pre-clinical studies and undertake protein crystallization studies. Scale-up for clinical studies produced 3.4 g of the T84.66 minibody in the harvest. A portion of this material was purified yielding 180 mg of highly purified T84.66 minibody intended for pilot radioimmunoscintigraphy studies of carcinoembryonic antigen (CEA) positive disease.

[1]  P. Matsudaira.  A Practical guide to protein and peptide purification for microsequencing , 1989 .

[2]  R. Huber,et al.  Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from Staphylococcus aureus. , 1978, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[3]  A. George,et al.  Mammalian expression and secretion of functional single-chain Fv molecules. , 1994, The Journal of biological chemistry.

[4]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[5]  R. Gentz,et al.  Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent , 1988, Bio/Technology.

[6]  A. Wu,et al.  Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[7]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[8]  B. Snedecor,et al.  High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli , 1996, Bio/Technology.

[9]  S M Larson,et al.  Radioimmunodetection in cancer identification. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. George,et al.  Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. , 1998, Journal of immunological methods.

[11]  J M Esteban,et al.  Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[13]  L. Björck.  Protein L. A novel bacterial cell wall protein with affinity for Ig L chains. , 1988, Journal of immunology.

[14]  S. Larson,et al.  Single chain antigen binding protein (sFv CC49) , 1997, Cancer.

[15]  S. Batra,et al.  Effects of genetic engineering on the pharmacokinetics of antibodies. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[16]  R. Webster,et al.  Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. , 1997, Protein engineering.

[17]  S. Ho,et al.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. , 1989, Gene.

[18]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[19]  D. Goldenberg.  Perspectives on oncologic imaging with radiolabeled antibodies , 1997, Cancer.

[20]  N. Petrelli,et al.  Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Begent,et al.  Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. , 1995, Journal of immunological methods.

[22]  A. Wu,et al.  Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in pichia pastoris. The essential role of the N-domain. , 1998, Anticancer research.

[23]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J M Esteban,et al.  Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. , 1995, Cancer research.

[25]  M. Kozak,et al.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. , 1987, Journal of molecular biology.

[26]  P. Weiden,et al.  Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. , 1997, Clinical nuclear medicine.

[27]  A. B. Robinson,et al.  Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. , 1974, Current topics in cellular regulation.

[28]  R. Hawkins,et al.  Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.

[29]  G. Sfakianakis,et al.  A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. , 1999, Cancer investigation.

[30]  S. Hjertén,et al.  Protein chromatography on calcium phosphate columns. , 1956, Archives of biochemistry and biophysics.

[31]  J. Huston,et al.  Mammalian Cell Expression of Single–Chain Fv (sFv) Antibody Proteins and Their C–terminal Fusions with Interleukin–2 and Other Effector Domains , 1994, Bio/Technology.

[32]  A. Matus,et al.  A novel strategy for the immunological tagging of cDNA constructs. , 1993, Gene.

[33]  D. Vizard,et al.  Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. , 1994, BioTechniques.

[34]  J. Doroshow,et al.  Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. George,et al.  Single-chain Fv radioimmunotargeting. , 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[37]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.